Background/Aims: Reported associations of reproductive outcomes (RO) and polycystic ovary syndrome (PCOS) with genotypes of the Ile49Ser and -482A>G polymorphisms in the Anti-Müllerian hormone (AMH) gene and its type II receptor (AMHRII), respectively, have conflicting results. Methods: PubMed, Google Scholar and Science Direct databases were searched for studies that investigated Ile49Ser and -482A>G in RO and PCOS. Using the metaanalytic approach, we estimated risk (odds ratio [OR] with 95% confidence intervals) using standard genetic models. Results: All calculated summary effects were non-significant. Overall associations of Ile49Ser and -482A>G with RO were absent (OR 0.95-0.99, P = 0.76-0.96) but implied increased risk in PCOS (OR 1.07-1.17, P = 0.49-0.55). Where heterogeneity of the pooled ORs were present, its sources were explored using the Galbraith plot. Detection and omission of the outlying studies in both polymorphisms not only erased heterogeneity of the recalculated pooled outcomes but also changed direction of association, where null effects turned to increased risk (Ile49Ser in RO) and increased risk became reduced risk . Implications of the Ile49Ser and -482A>G, effects pointed to protection for Caucasians N. Pabalan and E. Montagna have the same importance in the manuscript.
Introduction
Reproductive outcomes (RO) in women encompass a range of gynecological issues which include ovarian insufficiency and failure as well as infertility. Infertility which could be attributed to precursor conditions such as polycystic ovary syndrome (PCOS) involves failure to achieve pregnancy after a year of unprotected intercourse [1] . RO has become a global health issue warranting couples to seek assisted reproductive technology methods [2] . Success of these methods depends on variability of patient characteristics, much of which is attributed to genetic factors that regulate female reproductive function. Single nucleotide polymorphisms (SNPs) in coding regions in the signaling pathways of the ovary could play an important role in RO, as they are responsible for synthesis of hormone receptors, metabolic enzymes or transport molecules.
The Anti-Müllerian hormone (AMH) aka Müllerian inhibiting substance is homodimeric and a member of the transforming growth factor-beta (TGF-β) superfamily [3] . AMH in the female is produced exclusively by ovarian granulosa cells of pre-antral and small antral follicles [4] . Its concentration declines with age and become undetectable after menopause [5] . The number of antral follicles are strongly correlated with the size of primordial follicle pool [6] which indicate status of ovarian function and reserve as shown by serum AMH levels [7] . AMH is involved in the regulation of follicular growth [8] and continues to be expressed in the growing follicles until they have reached the appropriate size and differentiation state [9] . AMH with its serum has been shown to be a good indicator of a patient's follicular response to controlled ovarian stimulation with gonadotropins [7] . A meta-analysis has reported AMH to be a good predictor of ovarian response [10] .
The gene for AMH is located on the small arm of chromosome 19 and consists of 5 exons [11, 12] . AMH is produced as a pro-hormone, which after secretion undergoes cleavage to generate a transforming growth factor-C-terminal fragment [13] . AMH exerts its biological effects through the AMH type II receptor (AMHRII), which in turn activates AMH type I receptor (AMHRI) and creates a downstream signaling pathway. The human gene for AMHRII is located on chromosome 12, consists of 11 exons and is expressed in granulosa and theca cells [14] . Recent studies in normo-ovulatory women have demonstrated an association of the polymorphisms of AMH and its receptor (AMHRII) with estradiol levels during the early follicular phase of the menstrual cycle [15] . Therefore, genetic variants in the AMH and AMHRII genes may influence hormone function in folliculogenesis causing infertility. Two polymorphisms in the AMH gene and AMHRII are found at the Ile49Ser (rs10407022) and -482A>G (rs2002555) restriction sites, respectively [3] . Genetic studies have shown that these variants are associated with reproductive status of women which include infertility [16] and in the AMH signaling pathway, play a role in usage of the primordial follicle pool, and also affect follicle counts as well as folliculogenesis [17] . Carriers of the AMH 49Ser and -482G alleles have higher follicular phase estradiol levels compared to non-carriers [15, 18] . Also, carriers of the AMH 49Ser allele in PCOS, women were less likely to exhibit polycystic ovaries and low androgen levels (hyperandrogenism) [19] [20] [21] , suggesting a contribution of AMH polymorphism to the severity of PCOS. Considering these roles of AMH in regard to regulating ovarian function, it has been postulated that the genetic variants in the AMH signaling pathway could lead to an impaired reproductive function of women. Given the variable outcomes in the human reproduction investigations of the AMH and AMHRII variants, we performed a meta-analysis to evaluate the role of Ile49Ser and -482A>G in RO and PCOS. 
Materials and Methods
Selection of studies Using the terms "AMH", "Anti-Müllerian hormone", "polymorphism", "reproductive outcomes" and "polycystic ovary syndrome", we searched MEDLINE using PubMed, Science Direct and Google Scholar for association studies as of May 31, 2016 without language restrictions. References cited in the retrieved articles were also screened manually to identify additional eligible studies. Inclusion criteria included: (1) case-control study design evaluating the association between AMH and AMHRII polymorphisms and RO, as well as PCOS, (2) sufficient genotype frequency data presented to calculate the odds ratios (ORs) and 95% confidence intervals (CI).
Data extraction
Two investigators independently extracted data and reached consensus on all the items. The following information was obtained from each publication: first author's name, published year, country of origin, dominant ancestry of the study populations, study design, context of the study, type of ovarian response, use of the Hardy-Weinberg Equilibrium (HWE), AMH and AMHRII polymorphism studied, sample source, genotyping approach, matching information and genotype data. We extracted data that pertained to our investigation of RO and PCOS. We also calculated frequencies of the variant allele, deviations of the controls from HWE. Where studies reported the mean and 95% CI, SD was derived as follows:
.
Quality assessment of the studies
We used the Clark-Baudouin Score (CBS) to evaluate methodological quality of the included studies [22] . This scale emphasizes statistics (i.e. P values, power and corrections for multiplicity) and includes genotyping methods as well as HWE. These among others, were addressed in several of the included papers. Thus we felt this to be most appropriate in assessing the methodological quality of the included studies. For case-control studies, CBS scores range from 0 (worst) to 10 (best) where scoring is based on quality (low for <5 and high for ≥5).
Meta-analysis
We investigated polymorphisms in AMH (Ile49Ser) and AMHRII (-482A>G) whose influence was estimated using the standard genetic models (homozygous, recessive, dominant and codominant). These associations were expressed as OR, 95% CI. Raw data for genotype frequencies, without adjustment, were used for calculating study-specific estimates of the OR. Significance of the pooled estimates was determined by the Z-test. Pooled estimates were obtained using either the fixed [23] (in the absence of heterogeneity) or random [24] (in its presence) effects models. Heterogeneity between studies was estimated using the χ 2 -based Q test [25] . Recognizing the low power of this test [26] , significance threshold was set at P = 0.10. We also quantified heterogeneity with the I 2 statistic which measures the degree of inconsistency among studies [27] . Significance was set at a P-value of ≤0.05 throughout except in heterogeneity estimation. Pooled estimates were subjected to sensitivity analysis which involved omitting one study at a time and recalculating the pooled estimates, to test for robustness of the summary effect. Subgroup analysis based on ethnicity was performed on those comprising of three or more studies. Data were analyzed using Review Manager 5.3 (Copenhagen: Nordic Cochrane Centre, Cochrane Collaboration, 2014) and SigmaStat 2.3 (Systat Software, San Jose, CA). All comparisons in our meta-analysis had <10 studies, and because of the low sensitivity of the qualitative and quantitative tests [28] , we did not investigate publication bias. Figure 1 outlines our study selection process in a flowchart following PRISMA (Preferred Reporting Items for Systematic Reviews and Meta-Analyses) guidelines [29] . We identified a total of 116 citations during the initial search, from which 17 were omitted following a review of titles and abstracts. We retrieved the remaining 99 abstracts which after review, 73 Table 1 and 2. Nine and six examined RO [16, [30] [31] [32] [33] [34] [35] [36] [37] and PCOS [19, [38] [39] [40] [41] [42] , respectively, and one study examined both [43] . Publication years of the included studies ranged from 2008 to 2016. Eight studies each were Asian [33, [35] [36] [37] [40] [41] [42] [43] and Caucasian [16, 19, 30-32, 34, 38, 39] . In terms of study context for Ile49Ser, five focused on infertility or ovarian insufficiency [16, 33, 36, 37, 43] and three addressed stimulation issues [30, 32, 35] . One was about assisted reproductive technology [31] and another addressed follicle recruitment [34] . All 16 articles addressed HWE and used blood as tissue source, but none of them explicitly mention about controls being matched to cases. For -482A>G, the studies addressed relationships between genes [39, 42] , hormone levels [19, 38, 41] and PCOS. One PCOS study engaged in haplotype analysis [40] . Based on the CBS scores, methodological quality of the included papers was high (mean and standard deviation of 6.40 ±0.84 and 5.57 ±1.40 for RO and PCOS, respectively). Tables 3 and 4 summarize the sample sizes, genotype and minor allele frequencies as well as HWE values for both polymorphisms in RO and PCOS. Controls in two studies for PCOS deviated from HWE [41, 42] . Where genotype frequency values are zero, we applied the Laplace correction by adding a pseudo-count of one to all values of the data set [44] prior to generating the forest plots. Tables 5 and 6 show no evidence of significant associations in all comparisons. The Ile49Ser overall effects in RO were essentially null (OR 0.95-0.99, P = 0.76-0.98) but implied increased risk in PCOS (OR 1.07-1.16, P = 0.51-0.55). Outlier analysis changed these overall Figure 2 shows a pooled OR of <1.00 (OR 0.95). Figure 3 identifies two outlier studies below the -2 confidence limit [16, 43] . Figure 4 shows the forest plot without the outliers that resulted in a changed pooled OR of >1 (OR 1.17). The -482A>G overall effects yielded both an implied increased risk in RO (OR 1.02-1.24, P = 0.28-0.82) and in PCOS (OR 1.05-1.31, P = 0.54-0.80). Asian Ile49Ser effects were variable for RO but implied increased risk in -482A>G in PCOS (OR 1.14- 
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Included studies
Meta-analysis
Heterogeneity analysis
Effects of outlier treatment on the overall pooled ORs in both polymorphisms was generally erasure of heterogeneity (Tables 5 and 6 ). Figures 2 to 4 show effects of outlier treatment in the dominant model of Ile49Ser on heterogeneity. Figure 2 shows the preoutlier pooled OR with moderate heterogeneity (P = 0.02, I 2 = 58%) and Figure 4 shows the post-outlier effect resulting in zero heterogeneity (P = 0.74, I 2 = 0%). Zero heterogeneity (I Ile49Ser effects in RO; and (iii) all homozygous and recessive effects (overall and subgroups) in -482A>G of both polymorphisms (Tables 5 and 6 ). Table 7 summarizes the changes in association resulting from sensitivity treatment. These changes affected all comparisons in every genetic model. Of the four comparisons, Ile49Ser in RO was least robust as the pooled ORs were altered with omission of a total of five studies [16, 30, 31, 36, 43] in every genetic model. By contrast, -482A>G was non-robust in the dominant model only, attributed to two studies [32, 43] . In terms of genetic model, pooled ORs in the homozygous and recessive models were deemed robust in -482A>G comparisons.
Sensitivity analysis
Discussion
With a sample size of 9,210 for both polymorphisms in RO and PCOS, our meta-analysis has shown that genotypes in the AMH and AMHRII genes are not significantly associated with RO and PCOS. Despite the non-significance, subgroup analysis delineated pooled effects between the ethnic groups and outlier treatment erased heterogeneity, which thus rendered greater confidence in the post-outlier results. However, another consequence of outlier treatment was change in direction of association such that the original close to null pooled ORs became 1.2-fold increased risk in Ile49Ser and 1.2-fold increased risk became 
Cellular Physiology and Biochemistry
To our knowledge, this is the first meta-analysis to address AMH associations in both RO and PCOS. Study specific findings of RO and PCOS were variable, with contradictions among the results. Absence of associations between the AMH and AMHRII polymorphisms and ovarian stimulation have been reported [30, 35] and contradicted in another study [31] . Regarding ovarian insufficiency, findings of no association [36] were countered by other studies that found associations [33, 43] . Associations of Ile49Ser and -482A>G with PCOS have been reported [38, 41, 43] but found absent in other studies [19, 39, 40, 42] . These findings indicate lack of consistency in the outcome of these association studies. Here, then enters the utility of our meta-analysis. AMH levels are currently used in clinical practice to predict response to stimulation [6] , its value is recognized in a range of clinical settings, from PCOS to ovarian assessment following cancer treatment [45] . PCOS has been found to cause significantly increased risk of ovarian hyperstimulation syndrome [46] . In addition, impact of AMH receptor polymorphism have been studied in other diseases such as breast cancer [47] and cryptorchidism [48] .
Hence, reproductive studies in women have focused on the role of serum AMH as marker for ovarian response and reserve [31] . AMH has the advantage of having relatively stable levels throughout the menstrual cycle [49, 50] and is more accurate in providing information on the expected ovarian response to controlled stimulation [50] . However, AMH is limited in extreme responses as it is not reliably predictive in this situation, and also its value has been questioned [51] . Nevertheless, considering the important role of the AMH signaling pathway in regulating sensitivity in the ovary and follicular recruitment, it is appropriate to consider that variation in the genes encoding key proteins in the pathway may influence ovarian response. Genetic variation in AMH studies demonstrated that Ile49Ser and −482A>G were associated with an increase in estradiol (E2) and AMH levels during the follicular phase of the menstrual cycle in healthy normo-ovulatory women [15] as well as with the number of embryos produced [52] . Significant differences between certain subgroups were found following controlled ovarian stimulation amongst women with wild type for the AMH polymorphism [31] . In addition, women with wild-type for the AMHRII polymorphism had a higher number of follicles, and those with higher peak serum E2 levels required a lower gonadotropin dose [31] . These polymorphisms have been demonstrated to be of predictive utility in ovarian stimulation procedures (reviewed in [53] ).
Interpreting the results of this meta-analysis warrant awareness of its strengths and limitations. Strengths include the following: (i) all tissue sources were blood; (ii) all of the studies addressed the HWE issues; (iii) efficiency of outlier treatment in erasing heterogeneity and altering direction of association enabling the findings to be without the baggage of variability; (iii) zero heterogeneity in most comparisons of the -482A>G polymorphism. (iv) Pooled ORs of -482A>G in RO and PCOS were robust in the homozygous and recessive models. On the other hand, there are a number of limitations in our study: (i) [32, 34, [38] [39] [40] .
(ii) The -482A>G comparisons had a small number of studies thus with limited statistical power; (iii) since we included studies whose controls deviated from the HWE, we risked methodological weakness, such as biased selection of subjects, genotyping errors and population stratification [54] . However, non-significance remained with omission of these studies followed by recalculation. (iv) Genotyping approaches were not uniform although most of the studies used PCR (Polymerase Chain Reaction). (v) Pooled ORs in Ile49Ser were generally not robust.
Conclusion
It is possible that Ile49Ser and -482A>G do not play any direct functional role in RO and PCOS, but are in linkage disequilibrium (LD) with other polymorphisms [19] . It is also likely that variants in other than AMH or AMHRII are relevant to RO and PCOS [15, 31, 32, 40] . It is possible that the Ile49Ser and -482A>G polymorphisms are merely markers for the truly functional polymorphism elsewhere in these genes [15] . Lazaros et al [32] suggested a concerted effect between -482A>G and 1749C4T, since both polymorphisms in AMHRII were found to be in strong LD. Genome wide association studies may be promising as did a recent one that found significant correlation with ovarian response [55] . It is conceivable that RO and PCOS related to any one locus will be small because gene-gene as well as gene-environment interactions are likely to operate. Genotyping the AMH and AMHRII polymorphisms together with some additional markers may provide a means of identifying RO. Meanwhile, further studies regarding other SNPs (or haplotypes) in the AMH and AMHRII genes may help better understand their roles in RO/PCOS. Since potential biases and confounders could not be ruled out completely in this meta-analysis, additional large case-control studies or later update meta-analysis may be warranted to validate or modify our findings. It would help that well-designed studies based on sample sizes commensurate with detection of small genotypic risks should allow more definitive conclusions about the association of AMH and AMHRII polymorphisms and RO/PCOS. 
